{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:36:48Z","timestamp":1793716608533,"version":"4.6.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017433","name":"That Man May See","doi-asserted-by":"publisher","award":["AW212211"],"award-info":[{"award-number":["AW212211"]}],"id":[{"id":"10.13039\/100017433","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Background\n<\/jats:title>\n                <jats:p>Ocular rosacea is common and is often managed with long-term antibiotic treatment. Doxycycline is the most commonly selected antibiotic for the treatment of rosacea. As there is no established standard of care treatment dose for rosacea, prescribed doses of doxycycline vary widely. The FDA classifies 40\u00a0mg daily dose of doxycycline for ocular rosacea as sub-microbial in comparison to an antibiotic dose of 200\u00a0mg daily. However, this \u201csub-microbial\u201d dose has never been evaluated in patients with ocular rosacea, and even the sub-microbial dose has potential to alter systemic mucosa flora. Here, we present a randomized controlled trial using RNA sequencing to fully characterize the impact of sub-microbial antibiotic dosing of doxycycline on antimicrobial resistance and bacterial composition of the ocular and gut flora.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In a triple-masked parallel randomized control trial, patients with ocular rosacea will be randomized to three arms: a 40-mg dose of doxycycline, a 200-mg antibiotic dose of doxycycline, or placebo. Collected rectal and lower eyelid samples will be compared for frequency of antimicrobial resistance genetic determinants and microbiome diversity. A subjective ocular surface disease index survey and objective tear breakup time measurement will be determined.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>These results will enhance our understanding of the overall systemic impact of long-term systemic sub-microbial antibiotic dosing for the treatment of chronic recurrent ocular inflammatory diseases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This trial was registered on ClinicalTrials.org (NCT05296837) on March 22, 2022.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06948-9","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T15:03:55Z","timestamp":1671548635000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ocular Rosacea microBiome Study (ORBS)\u2014sub-microbial versus antibiotic dosing of doxycycline versus placebo in treatment of symptomatic ocular rosacea: study protocol for a parallel-arm randomized clinical trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Hamidah","family":"Mahmud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gonzales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Schallhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilda","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Cavallino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Lietman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy","family":"Doan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1791-5509","authenticated-orcid":false,"given":"Gerami D.","family":"Seitzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"issue":"2","key":"6948_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/ceo.13900","volume":"49","author":"S Tavassoli","year":"2021","unstructured":"Tavassoli S, Wong N, Chan E. Ocular manifestations of rosacea: a clinical review. Clin Exp Ophthalmol. 2021;49(2):104\u201317. https:\/\/doi.org\/10.1111\/ceo.13900.","journal-title":"Clin Exp Ophthalmol"},{"key":"6948_CR2","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/S0161-6420(97)30015-3","volume":"104","author":"EK Akpek","year":"1997","unstructured":"Akpek EK, Merchant A, Pinar V, Foster CS. Ocular rosacea: patient characteristics and follow-up. Ophthalmology. 1997;104:1863\u20137.","journal-title":"Ophthalmology"},{"key":"6948_CR3","doi-asserted-by":"crossref","unstructured":"Schaller M, Kemny L, Havlickova B, Jackson JM, Ambroziak M, Lynde C, Gooderham M, Remenyik E, Del Rosso J, Weglowska J, Chavda R, Kerrouche N, Dirschka T, Johnson S. A randomized phase 3b\/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. J Am Acad Dermatol. 2020;82(2):336\u2013343. Erratum in: J Am Acad Dermatol. 2021;84(5):1506.","DOI":"10.1016\/j.jaad.2019.05.063"},{"key":"6948_CR4","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaad.2017.04.1127","volume":"77","author":"M Zhang","year":"2017","unstructured":"Zhang M, Silverberg JI, Kaffenberger BH. Prescription patterns and costs of acne\/rosacea medications in Medicare patients vary by prescriber specialty. J Am Acad Dermatol. 2017;77:448-455.e2.","journal-title":"J Am Acad Dermatol"},{"key":"6948_CR5","first-page":"573","volume":"7","author":"JQ Del Rosso","year":"2008","unstructured":"Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol. 2008;7:573\u20136.","journal-title":"J Drugs Dermatol"},{"key":"6948_CR6","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1902\/jop.2008.070375","volume":"79","author":"PM Preshaw","year":"2008","unstructured":"Preshaw PM, Novak MJ, Mellonig J, Magnusson I, Polson A, Giannobile WV, Rowland RW, Thomas J, Walker C, Dawson DR, Sharkey D, Bradshaw MH. Modified-release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease. J Periodontol. 2008;79:440\u201352.","journal-title":"J Periodontol"},{"key":"6948_CR7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1001\/archderm.139.4.459","volume":"139","author":"R Skidmore","year":"2003","unstructured":"Skidmore R, Kovach R, Walker C, Thomas J, Bradshaw M, Leyden J, Powala C, Ashley R. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139:459\u201364.","journal-title":"Arch Dermatol"},{"key":"6948_CR8","unstructured":"Anon. Periostat [package insert]. Place of publication: Galderma; 2001."},{"key":"6948_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586","volume":"346","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hr\u00f3bjartsson A, Schulz KF, Parulekar WR, Krle\u017ea-Jeri\u0107 K, Laupacis A, Moher D. SPIRIT 2013 Explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346: e7586.","journal-title":"BMJ"},{"issue":"3","key":"6948_CR10","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/hae.14270","volume":"27","author":"J Oldenburg","year":"2021","unstructured":"Oldenburg J, Tran H, Peyvandi F, Nu\u00f1ez R, Trask P, Chebon S, Mahlangu JN, Lehle M, Jim\u00e9nez-Yuste V, von Mackensen S. Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study. Haemophilia. 2021;27(3):398\u2013407.","journal-title":"Haemophilia"},{"issue":"9","key":"6948_CR11","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/cid\/cix141","volume":"64","author":"T Doan","year":"2017","unstructured":"Doan T, Arzika AM, Ray KJ, Cotter SY, Kim J, Maliki R, Zhong L, Zhou Z, Porco TC, Vanderschelden B, Keenan JD, Lietman TM. Gut microbial diversity in antibiotic-naive children after systemic antibiotic exposure: a randomized controlled trial. Clin Infect Dis. 2017;64(9):1147\u201353.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"6948_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/cid\/ciz455","volume":"70","author":"CE Oldenburg","year":"2020","unstructured":"Oldenburg CE, Hinterwirth A, Si A, Coulibaly B, Ouermi L, Dah C, Tapsoba C, Cummings SL, Zhong L, Chen C, Sarkar S, Barnighausen T, Lietman TM, Keenan JD, Doan T. Gut resistome after oral antibiotics in preschool children in burkina faso: a randomized, controlled trial. Clin Infect Dis. 2020;70(3):525\u20137.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"6948_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/2042098614554919","volume":"5","author":"C Llor","year":"2014","unstructured":"Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther Adv Drug Saf. 2014;5(6):229\u201341. https:\/\/doi.org\/10.1177\/2042098614554919.","journal-title":"Ther Adv Drug Saf"},{"key":"6948_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jgar.2021.11.003","volume":"29","author":"S Esposito","year":"2022","unstructured":"Esposito S, Biasucci G, Pasini A, et al. Antibiotic resistance in paediatric febrile urinary tract infections. J Glob Antimicrob Resist. 2022;29:499\u2013506. https:\/\/doi.org\/10.1016\/j.jgar.2021.11.003.","journal-title":"J Glob Antimicrob Resist"},{"issue":"9","key":"6948_CR15","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s40266-020-00786-7","volume":"37","author":"MN Al-Hasan","year":"2020","unstructured":"Al-Hasan MN, Al-Jaghbeer MJ. Use of antibiotics in chronic obstructive pulmonary disease: what is their current role in older patients? Drugs Aging. 2020;37(9):627\u201333. https:\/\/doi.org\/10.1007\/s40266-020-00786-7.","journal-title":"Drugs Aging"},{"key":"6948_CR16","doi-asserted-by":"publisher","unstructured":"Su ZT, Zenilman JM, Sfanos KS, Herati AS. Management of chronic bacterial prostatitis. Curr Urol Rep. 2020;21(7):29. Published 2020 Jun 3. https:\/\/doi.org\/10.1007\/s11934-020-00978-z.","DOI":"10.1007\/s11934-020-00978-z"},{"issue":"10","key":"6948_CR17","doi-asserted-by":"publisher","first-page":"fnw081","DOI":"10.1093\/femsle\/fnw081","volume":"363","author":"J Cervantes","year":"2016","unstructured":"Cervantes J. Use your antibiotics wisely. Consequences to the intestinal microbiome. FEMS Microbiol Lett. 2016;363(10):fnw081. https:\/\/doi.org\/10.1093\/femsle\/fnw081.","journal-title":"FEMS Microbiol Lett"},{"issue":"2","key":"6948_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/jpids\/piy065","volume":"8","author":"A Khan","year":"2019","unstructured":"Khan A, Jhaveri R, Seed PC, Arshad M. Update on associated risk factors, diagnosis, and management of recurrent urinary tract infections in children. J Pediatric Infect Dis Soc. 2019;8(2):152\u20139. https:\/\/doi.org\/10.1093\/jpids\/piy065.","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"5","key":"6948_CR19","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41390-021-01613-4","volume":"91","author":"J Sun","year":"2022","unstructured":"Sun J, Li Y. Long-term, low-dose macrolide antibiotic treatment in pediatric chronic airway diseases. Pediatr Res. 2022;91(5):1036\u201342. https:\/\/doi.org\/10.1038\/s41390-021-01613-4.","journal-title":"Pediatr Res"},{"key":"6948_CR20","doi-asserted-by":"publisher","unstructured":"Ahmed H, Davies F, Francis N, Farewell D, Butler C, Paranjothy S. Long-term antibiotics for prevention of recurrent urinary tract infection in older adults: systematic review and meta-analysis of randomised trials.\u00a0BMJ Open. 2017;7(5):e015233. Published 2017 May 29. https:\/\/doi.org\/10.1136\/bmjopen-2016-015233.","DOI":"10.1136\/bmjopen-2016-015233"},{"key":"6948_CR21","doi-asserted-by":"publisher","unstructured":"Hahn A, Burrell A, Fanous H, et al. Antibiotic multidrug resistance in the cystic fibrosis airway microbiome is associated with decreased diversity.\u00a0Heliyon. 2018;4(9):e00795. Published 2018 Sep 17. https:\/\/doi.org\/10.1016\/j.heliyon.2018.e00795.","DOI":"10.1016\/j.heliyon.2018.e00795"},{"issue":"9944","key":"6948_CR22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S0140-6736(14)61137-5","volume":"384","author":"LJ Sherrard","year":"2014","unstructured":"Sherrard LJ, Tunney MM, Elborn JS. Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis. Lancet. 2014;384(9944):703\u201313. https:\/\/doi.org\/10.1016\/S0140-6736(14)61137-5.","journal-title":"Lancet"},{"issue":"1","key":"6948_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2021.1900995","volume":"13","author":"K Kang","year":"2021","unstructured":"Kang K, Imamovic L, Misiakou MA, et al. Expansion and persistence of antibiotic-specific resistance genes following antibiotic treatment. Gut Microbes. 2021;13(1):1\u201319. https:\/\/doi.org\/10.1080\/19490976.2021.1900995.","journal-title":"Gut Microbes"},{"issue":"3","key":"6948_CR24","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000443360","volume":"34","author":"K Lange","year":"2016","unstructured":"Lange K, Buerger M, Stallmach A, Bruns T. Effects of Antibiotics on Gut Microbiota. Dig Dis. 2016;34(3):260\u20138. https:\/\/doi.org\/10.1159\/000443360.","journal-title":"Dig Dis"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06948-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06948-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06948-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T03:20:22Z","timestamp":1671852022000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06948-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6948"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06948-9","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]},"assertion":[{"value":"21 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The University of California San Francisco Institutional Review Board has given ethical approval for the trial and will review the trial annually (21\u201334725) and has been provided for review (Supplementary material ). Written, informed consent to participate will be obtained from all participants at enrollment into the trial. Patients may also consent to provide their de-identified data for ancillary studies. There is no financial cost to the participants.Study personnel will approach eligible participants. In a private setting, the study team member will explain the study as well as detailed information about what study participation entails. The study team member will clarify that participation in the study is voluntary, that participation may be stopped at any time, and that all collected data will be kept confidential and securely stored. The study team member will ensure comprehension by inviting the participant to ask questions and will provide time to consider participation. When providing consent, both the study team member and participants will sign two copies of the consent document. One copy will be given to the participant and the other will be kept for study reference.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written, informed consent to publish de-identified results will be obtained from all participants. A model consent form is provided (Supplementary material ).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1033"}}